Erratum to: Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists (Angiogenesis, (2017), 20, 2, (233-241), 10.1007/s10456-017-9549-6);Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists

Angiogenesis

Volumn 20, Issue 2, 2017, Pages 233-241

  Bani, MariaRosa ^a   Decio, Alessandra ^a   Giavazzi, Raffaella ^a   Ghilardi, Carmen ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Angiogenesis; Drug resistance; Ovarian adenocarcinoma; P glycoprotein; Tumor endothelial cells; Tyrosine kinase inhibitor

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CEDIRANIB; CISPLATIN; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB; ABC TRANSPORTER SUBFAMILY B; ABCB1 PROTEIN, HUMAN; ANGIOGENESIS INHIBITOR; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ENDOTHELIAL CELL; TUMOR VASCULARIZATION; UPREGULATION; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

3T3 CELLS; ANGIOGENESIS INHIBITORS; ANIMALS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY B; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85017106819     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-017-9558-5     Document Type: Erratum

References (37)

1. McMillin DW, Negri JM, Mitsiades CS (2013) The role of tumour–stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 12:217–228. doi:10.1038/nrd3870
2. van Beijnum JR, Nowak-Sliwinska P, Huijbers EJM et al (2015) The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev 67:441–461. doi:10.1124/pr.114.010215
3. Huijbers EJM, van Beijnum JR, Thijssen VL et al (2016) Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother 25:26–37. doi:10.1016/j.drup.2016.02.002
4. Nagy JA, Chang S-H, Shih S-C et al (2010) Heterogeneity of the tumor vasculature. Semin Thromb Hemost 36:321–331. doi:10.1055/s-0030-1253454
5. Heldin C-H, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer 4:806–813. doi:10.1038/nrc1456
6. Hida K, Akiyama K, Ohga N et al (2013) Tumour endothelial cells acquire drug resistance in a tumour microenvironment. J Biochem (Tokyo) 153:243–249. doi:10.1093/jb/mvs152
7. Alessandri G, Chirivi RG, Fiorentini S et al (1999) Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. Clin Exp Metastas 17:655–662
8. Bussolati B, Deregibus MC, Camussi G (2010) Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies. Curr Vasc Pharmacol 8:220–232
9. Silini A, Ghilardi C, Figini S et al (2012) Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor’s proangiogenic microenvironment. Cell Mol Life Sci CMLS 69:1167–1178. doi:10.1007/s00018-011-0862-8
10. Ghilardi C, Silini A, Figini S et al (2015) Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2. Oncotarget 6:28389–28400. doi:10.18632/oncotarget.4949
11. Hida K, Maishi N, Torii C, Hida Y (2016) Tumor angiogenesis—characteristics of tumor endothelial cells. Int J Clin Oncol 21:206–212. doi:10.1007/s10147-016-0957-1
12. St Croix B, Rago C, Velculescu V et al (2000) Genes expressed in human tumor endothelium. Science 289:1197–1202
13. Lu C, Bonome T, Li Y et al (2007) Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67:1757–1768. doi:10.1158/0008-5472.CAN-06-3700
14. Seaman S, Stevens J, Yang MY et al (2007) Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11:539–554. doi:10.1016/j.ccr.2007.04.017
15. Ghilardi C, Chiorino G, Dossi R et al (2008) Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genom 9:201. doi:10.1186/1471-2164-9-201
16. Bussolati B, Deambrosis I, Russo S et al (2003) Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J Off Publ Fed Am Soc Exp Biol 17:1159–1161. doi:10.1096/fj.02-0557fje
17. Grange C, Bussolati B, Bruno S et al (2006) Isolation and characterization of human breast tumor-derived endothelial cells. Oncol Rep 15:381–386
18. Xiong Y-Q, Sun H-C, Zhang W et al (2009) Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res Off J Am Assoc Cancer Res 15:4838–4846. doi:10.1158/1078-0432.CCR-08-2780
19. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714–726. doi:10.1038/nrc3599
20. Camassei FD, Arancia G, Cianfriglia M et al (2002) Nephroblastoma: multidrug-resistance p-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Am J Clin Pathol 117:484–490. doi:10.1309/L44X-L5DN-1VHV-X30N
21. Fattori S, Becherini F, Cianfriglia M et al (2007) Human brain tumors: multidrug-resistance p-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Virchows Arch Int J Pathol 451:81–87. doi:10.1007/s00428-007-0401-z
22. Ginguené C, Champier J, Maallem S et al (2010) P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas. Brain Pathol Zur Switz 20:926–935. doi:10.1111/j.1750-3639.2010.00389.x
23. Akiyama K, Ohga N, Hida Y et al (2012) Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol 180:1283–1293. doi:10.1016/j.ajpath.2011.11.029
24. Ambudkar SV, Dey S, Hrycyna CA et al (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–398. doi:10.1146/annurev.pharmtox.39.1.361
25. Amin ML (2013) P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7:27–34. doi:10.4137/DTI.S12519
26. Gotink KJ, Verheul HMW (2010) Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13:1–14. doi:10.1007/s10456-009-9160-6
27. Zhang Y, Wang Q (2013) Sunitinib reverse multidrug resistance in gastric cancer cells by modulating Stat3 and inhibiting P-gp function. Cell Biochem Biophys 67:575–581. doi:10.1007/s12013-013-9544-5
28. Tao L-Y, Liang Y-J, Wang F et al (2009) Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol 64:961–969. doi:10.1007/s00280-009-0949-1
29. Mi Y, Lou L (2007) ZD6474 reverses multidrug resistance by directly inhibiting the function of p-glycoprotein. Br J Cancer 97:934–940. doi:10.1038/sj.bjc.6603985
30. Jovelet C, Bénard J, Forestier F et al (2012) Inhibition of p-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. Eur J Pharm Sci Off J Eur Fed Pharm Sci 46:484–491. doi:10.1016/j.ejps.2012.03.012
31. Cesca M, Frapolli R, Berndt A et al (2009) The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. Neoplasia N Y N 11:1155–1164
32. Akiyama K, Maishi N, Ohga N et al (2015) Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic paclitaxel. Am J Pathol 185:572–580. doi:10.1016/j.ajpath.2014.10.017
33. Alessandri G, Chirivi RG, Castellani P et al (1998) Isolation and characterization of human tumor-derived capillary endothelial cells: role of oncofetal fibronectin. Lab Investig J Tech Methods Pathol 78:127–128
34. van Beijnum JR, Rousch M, Castermans K et al (2008) Isolation of endothelial cells from fresh tissues. Nat Protoc 3:1085–1091
35. Jaffe EA, Nachman RL, Becker CG, Minick CR (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52:2745–2756. doi:10.1172/JCI107470
36. Bonezzi K, Belotti D, North BJ et al (2012) Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia N Y N 14:846–854
37. Workman P, Aboagye EO, Balkwill F et al (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555–1577. doi:10.1038/sj.bjc.6605642